Hutchmed China Limited (HCM) Directors and Executive Officers

Officers & Directors

Executive Director:
- Christian Hogg: Founder and CEO of Hutchmed

Non-Executive Director:
- Simon To: Senior Managing Director at Temasek International and Head of China
- Francis Leung: Chairman and CEO of CVC Asia Pacific
- Dr. Liu Jiren: Co-founder and Chairman of Neusoft Corporation

Independent Non-Executive Director:
- Dr. Li Lu: Co-founder and Chairman of Himalaya Capital
- Dr. Joan Shen: General Manager at Intel Asia Pacific Research and Development Ltd.
- Dr. Jinzi J. Wu: Founder and Managing Partner of Zebra Investment Advisors

It is important to note that this information may be outdated and subject to change

Hutchmed china Limited currently has 780 employees.

News about Hutchmed china Limited Key Personnel

HUTCHMEDs ORPATHYS Approval: A Game-Changer for NSCLC Treatment Amidst Financial Resurgence

ArticleIn a defining moment for lung cancer treatment in China, HUTCHMED (China) Limited has secured full approval from the National Medical Products Administration (NMPA) for its groundbreaking drug ORPATHYS (savolitinib). This approval specifically targets patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who possess MET Exon 14 alterations. Notably, the indication has now expanded to include treatment-naïve patients, marking a significant milestone in the fight against this challenging disease.The news comes at a pivotal time for HUTCHMED, as the company reports a notable financial turnaround in its fourth quarter of 2023. The return on assets (ROA) surged to an impressive ...

HUTCHMED Strengthens Leadership and Showcases Breakthrough Oncology Data Ahead of Key Medical Conferences

HUTCHMED (China) Limited, a prominent biopharmaceutical company dedicated to advancing innovative oncology and hematology treatments, has announced the appointment of Dr. Chaohong Hu (Dr. Mary Hu) as an Independent Non-executive Director and member of the Board s Technical Committee, effective November 21, 2024. This strategic appointment reflects HUTCHMED’s commitment to enhancing its governance and technical expertise amid its ongoing growth trajectory in the competitive pharmaceutical landscape.Dr. Hu s extensive background in clinical research, coupled with her proven leadership experience, positions her as a valuable asset to HUTCHMED’s board. Her addition is anticipated to bolster the company s str...